The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms’ tumor patients

Abstract Background Wilms’ tumor (WT) is a common renal malignancy in children. Although certain patient groups exhibit high survival rates, those experiencing recurrence, metastasis, or chemoresistance face significant challenges. The identification of reliable prognostic markers is essential for a...

Full description

Saved in:
Bibliographic Details
Main Authors: Kongkong Cui, Jie Lin, Peng Hong, Honggang Fang, Zaihong Hu, Zhiqiang Gao, Xiaomao Tian, Qinlin Shi, Guanghui Wei
Format: Article
Language:English
Published: BMC 2025-06-01
Series:BMC Cancer
Subjects:
Online Access:https://doi.org/10.1186/s12885-025-14391-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850225871013543936
author Kongkong Cui
Jie Lin
Peng Hong
Honggang Fang
Zaihong Hu
Zhiqiang Gao
Xiaomao Tian
Qinlin Shi
Guanghui Wei
author_facet Kongkong Cui
Jie Lin
Peng Hong
Honggang Fang
Zaihong Hu
Zhiqiang Gao
Xiaomao Tian
Qinlin Shi
Guanghui Wei
author_sort Kongkong Cui
collection DOAJ
description Abstract Background Wilms’ tumor (WT) is a common renal malignancy in children. Although certain patient groups exhibit high survival rates, those experiencing recurrence, metastasis, or chemoresistance face significant challenges. The identification of reliable prognostic markers is essential for adapting treatment strategies to enhance survival rates and reduce chemotherapy-related adverse events (CRAEs). Methods This study included patients diagnosed with WT at our institution. Inflammatory biomarkers were measured from pre-treatment blood tests, and their associations with event-free survival (EFS) and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression analyses. The relationship between biomarkers and CRAEs was examined through logistic regression. Results Multifactorial Cox regression analysis identified tumor stage (HR = 4.68, 95% CI: 1.58–13.87, p = 0.005), pan-immune-inflammation value (PIV) (HR = 3.94, 95% CI: 1.80–8.60, p < 0.001), and neutrophil-to-lymphocyte ratio (NLR) (HR = 0.40, 95% CI: 0.18–0.90, p = 0.027) as independent prognostic factors for EFS. Multivariate Cox regression revealed that stage IV (HR = 12.24, 95% CI: 1.56–95.85, p = 0.017) and PIV levels exceeding 246.4 (HR = 5.50, 95% CI: 2.13–14.19, p < 0.001) were significant predictors for OS. Additionally, high PIV (OR 2.32, 95% CI: 1.15–4.67, p = 0.018) independently predicted the occurrence of CRAEs. Conclusion WT patients with higher PIV levels showed significant associations with poorer EFS, worse OS, and an increased likelihood of developing CRAEs during treatment.
format Article
id doaj-art-c2c0bd2de2b646ac8b4932971e0e4f90
institution OA Journals
issn 1471-2407
language English
publishDate 2025-06-01
publisher BMC
record_format Article
series BMC Cancer
spelling doaj-art-c2c0bd2de2b646ac8b4932971e0e4f902025-08-20T02:05:13ZengBMCBMC Cancer1471-24072025-06-0125111010.1186/s12885-025-14391-7The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms’ tumor patientsKongkong Cui0Jie Lin1Peng Hong2Honggang Fang3Zaihong Hu4Zhiqiang Gao5Xiaomao Tian6Qinlin Shi7Guanghui Wei8Department of Urology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and DisordersDepartment of Urology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and DisordersDepartment of Urology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and DisordersDepartment of Urology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and DisordersDepartment of Urology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and DisordersDepartment of Urology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and DisordersDepartment of Urology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and DisordersDepartment of Urology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and DisordersDepartment of Urology, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and DisordersAbstract Background Wilms’ tumor (WT) is a common renal malignancy in children. Although certain patient groups exhibit high survival rates, those experiencing recurrence, metastasis, or chemoresistance face significant challenges. The identification of reliable prognostic markers is essential for adapting treatment strategies to enhance survival rates and reduce chemotherapy-related adverse events (CRAEs). Methods This study included patients diagnosed with WT at our institution. Inflammatory biomarkers were measured from pre-treatment blood tests, and their associations with event-free survival (EFS) and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression analyses. The relationship between biomarkers and CRAEs was examined through logistic regression. Results Multifactorial Cox regression analysis identified tumor stage (HR = 4.68, 95% CI: 1.58–13.87, p = 0.005), pan-immune-inflammation value (PIV) (HR = 3.94, 95% CI: 1.80–8.60, p < 0.001), and neutrophil-to-lymphocyte ratio (NLR) (HR = 0.40, 95% CI: 0.18–0.90, p = 0.027) as independent prognostic factors for EFS. Multivariate Cox regression revealed that stage IV (HR = 12.24, 95% CI: 1.56–95.85, p = 0.017) and PIV levels exceeding 246.4 (HR = 5.50, 95% CI: 2.13–14.19, p < 0.001) were significant predictors for OS. Additionally, high PIV (OR 2.32, 95% CI: 1.15–4.67, p = 0.018) independently predicted the occurrence of CRAEs. Conclusion WT patients with higher PIV levels showed significant associations with poorer EFS, worse OS, and an increased likelihood of developing CRAEs during treatment.https://doi.org/10.1186/s12885-025-14391-7Wilms tumorRisk stratificationNomogramOverall survivalChemotherapy-related adverse events
spellingShingle Kongkong Cui
Jie Lin
Peng Hong
Honggang Fang
Zaihong Hu
Zhiqiang Gao
Xiaomao Tian
Qinlin Shi
Guanghui Wei
The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms’ tumor patients
BMC Cancer
Wilms tumor
Risk stratification
Nomogram
Overall survival
Chemotherapy-related adverse events
title The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms’ tumor patients
title_full The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms’ tumor patients
title_fullStr The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms’ tumor patients
title_full_unstemmed The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms’ tumor patients
title_short The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms’ tumor patients
title_sort pan immune inflammation value predicts prognosis and chemotherapy related adverse events in wilms tumor patients
topic Wilms tumor
Risk stratification
Nomogram
Overall survival
Chemotherapy-related adverse events
url https://doi.org/10.1186/s12885-025-14391-7
work_keys_str_mv AT kongkongcui thepanimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT jielin thepanimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT penghong thepanimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT honggangfang thepanimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT zaihonghu thepanimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT zhiqianggao thepanimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT xiaomaotian thepanimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT qinlinshi thepanimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT guanghuiwei thepanimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT kongkongcui panimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT jielin panimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT penghong panimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT honggangfang panimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT zaihonghu panimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT zhiqianggao panimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT xiaomaotian panimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT qinlinshi panimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients
AT guanghuiwei panimmuneinflammationvaluepredictsprognosisandchemotherapyrelatedadverseeventsinwilmstumorpatients